Company Overview - Saint Shine's main business focuses on innovative gene technology, providing integrated in vitro diagnostic solutions including diagnostic reagents, instruments, and third-party medical testing services [2] - The company has significantly enhanced its brand recognition and industry position, receiving high accolades from authoritative institutions both domestically and internationally [2] - Saint Shine has been listed in the global top 100 medical device companies for two consecutive years and has achieved various national certifications and awards [2] Financial Performance - For Q1 2025, the company reported a revenue of 475 million yuan, representing a year-on-year increase of 21.62% [2] - The net profit for the same period was 91.73 million yuan, showing a year-on-year growth of 13.22% [2] - The sales gross margin stood at 76.71% [2] Market Position - As of July 30, the company's stock closed at 22.26 yuan, with a rolling price-to-earnings (PE) ratio of 45.05 times [1] - The average PE ratio for the medical device industry is 55.15 times, with a median of 37.48 times, placing Saint Shine at the 82nd position in the industry ranking [1][3] - The total market capitalization of the company is approximately 12.897 billion yuan [1]
圣湘生物收盘下跌1.81%,滚动市盈率45.05倍,总市值128.97亿元